Dermavant Announces Publication in JAAD of Secondary Efficacy and Patient-Reported Outcomes in Phase 2b Clinical Trial of Tapinarof Cream for the Treatment of Plaque Psoriasis
LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced the publication of secondary efficacy and patient-reported outcomes from the Phase 2b randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis in The Journal of the American Academy of Dermatology (JAAD), the peer-reviewed scientific publication
